Related Experiment Video

Updated: Jul 5, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Management of engraftment arrhythmias associated with human-induced pluripotent stem cell-derived cardiomyocytes

Aixue Zhang1, Yufan Liu1, Yanwei Wei1

  • 1TEDA International Cardiovascular Hospital, Tianjin University, Tianjin, China.

Heart Rhythm
|July 3, 2026
PubMed

Insights

High-dose human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) transplantation increases the risk of early afterdepolarizations (EAs). Lower doses may mitigate EA occurrence, suggesting dose-dependent safety concerns for cell therapy in myocardial infarction.

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Stem Cell Therapy

Background:

  • Intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) shows promise for myocardial infarction treatment.
  • Early afterdepolarizations (EAs) occurring post-transplantation pose a significant barrier to the clinical translation of this cell therapy.

Purpose of the Study:

  • To characterize the nature of EAs following hiPSC-CM transplantation.
  • To identify critical risk factors associated with the development of EAs after hiPSC-CM transplantation.

Main Methods:

  • Patients undergoing coronary artery bypass grafting (CABG) with hiPSC-CM transplantation (experimental) or isolated CABG (control) were studied.
  • Experimental group patients received low (0.5×10^8) or high (1.5×10^8) doses of hiPSC-CMs.
  • EA characteristics were analyzed, and univariate logistic regression identified risk factors for EAs.

Main Results:

  • EAs occurred in 54.2% of hiPSC-CM recipients, originating from the injection site.
  • EAs progressed from paroxysmal to sustained episodes with increased heart rate and R-R variability.
  • Higher hiPSC-CM dose significantly correlated with increased EA incidence (83.3% high-dose vs. 25.0% low-dose; P=0.012).

Conclusions:

  • Early afterdepolarizations following hiPSC-CM transplantation appear to be driven by an automaticity mechanism.
  • The dosage of hiPSC-CMs is a significant factor influencing the incidence of EAs, highlighting a dose-dependent risk.
Abstract

Keywords:
Cardiac regenerationEngraftment arrhythmiasHeart failureIschemic cardiomyopathyiPS-Cardiomyocytes

More Related Videos

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs)11:13

Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs)

Published on: May 12, 2017

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...